All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Faron Pharmaceuticals Ltd.'s share price crashed by 86 percent to £1.04 (US$1.41) after it announced the phase III failure of Traumakine in the treatment of acute respiratory distress syndrome (ARDS).